 |
A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy CME DisclosuresRelease Date: January 31, 2008; Valid for credit through January 31, 2009 |
| Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | |
| Contents of This CME Activity | |
| The content of this internet activity, "A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy," was developed by the faculty.
To participate in this activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.
Facial lipoatrophy is a significant concern for many patients infected with HIV. Poly-L-lactic acid (PLA) may improve this condition, but there is little quality research into its efficacy. The current study follows 100 patients treated with PLA to address this issue. - A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy
Dianne L. Carey, MPH
David Baker, MB, ChB
Gary D. Rogers, MBBS, PhD
Kathy Petoumenos, PhD
John Chuah, MBBS, BSc (Med) Hons
Nicole Easey, BApplSc (Med Imaging)
Kirsty Machon, BA (Hons), MA
David A. Cooper, DSc, MD
Sean Emery, PhD
Andrew Carr, MD
Go to Test Questions |
| Legal Disclaimer | |
| The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Describe the problem of facial lipoatrophy in HIV and the application of poly-L-lactic acid (PLA) in medicine
- Identify objective outcomes of PLA treatment for patients with facial lipoatrophy and HIV infection
- Identify
subjective outcomes of PLA treatment for patients with facial lipoatrophy and HIV infection
- Specify adverse effects associated with PLA treatment for patients with facial lipoatrophy and HIV infection
Authors and Disclosures Dianne L. Carey, MPH
Disclosure: Dianne L. Carey, MPH, has disclosed no relevant financial
relationships. David Baker, MB, ChB
Disclosure: David Baker, MB, ChB, has disclosed no relevant financial relationships. Gary D. Rogers, MBBS, PhD
Disclosure: Gary D. Rogers, MBBS, PhD, has disclosed no relevant financial relationships. Kathy Petoumenos, PhD
Disclosure: Kathy Petoumenos, PhD,
has disclosed no relevant financial relationships. John Chuah, MBBS, BSc (Med) Hons
Disclosure: John Chuah, MBBS, BSc (Med) Hons, has disclosed no relevant financial relationships. Nicole Easey, BApplSc (Med Imaging)
Disclosure: Nicole Easey, BApplSc (Med Imaging), has disclosed no relevant financial relationships.
Kirsty Machon, BA (Hons), MA
Disclosure: Kirsty Machon, BA (Hons), MA, has disclosed no relevant financial relationships. David A. Cooper, DSc, MD
Disclosure: David A. Cooper, DSc, MD, has disclosed no relevant financial relationships. Sean Emery, PhD
Disclosure: Sean Emery, PhD, has disclosed that he receives
research support from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Chiron, Gilead Sciences, GlaxoSmithKline, Merck Sharp and Dohme, Roche, sanofi-aventis, and Virax. Dr. Emery has also disclosed that he has served as a consultant to, and/or has received travel support from, Bristol-Myers Squibb, Gilead Sciences, Neuropharmaceuticals Inc., Resistance Database Initiative, Roche, and Tibotec. Andrew Carr, MD
Disclosure: Andrew Carr, MD, has disclosed no relevant financial relationships. Charles P. Vega, MD
Disclosure: Charles P. Vega, MD, has disclosed that he has served as an advisor or consultant to Novartis, Inc. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
